ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nivolumab

Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.

Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,032 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 2015145 company-led studies, 14 open or runningNext primary completion: Feb 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only12410 open or runningphase 4since Nov 2, 2015Feb 27, 2007Feb 5, 2027phase 2 · NCT06946797
Ono Pharmaceuticalits history only144 open or runningphase 3since Oct 9, 2014Jan 26, 2009Dec 31, 2027phase 2 · NCT04566380
Pfizerits history only20 open or runningphase 2since Oct 7, 2015Oct 7, 2015none ahead
Ella Therapeuticsits history only10 open or runningphase 2since Aug 13, 2020Aug 13, 2020none ahead
ExcellaBioits history only10 open or runningphase 2since Oct 20, 2017Oct 20, 2017none ahead
Nilogen Oncosystemsits history only10 open or runningearly phase 1since Dec 3, 2017Dec 3, 2017none ahead
Rampart Healthits history only10 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead
USWM CT10 open or runningphase 2since Oct 26, 2022Oct 26, 2022none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of USWM CT only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2022First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT05601752 · 21 enrolled · United States, Canada, France and more

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study USWM CT leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05601752Ovarian Neoplasms · United States, Canada, France and more2TerminatedSep 30, 202521

How it is read

Names in the registry

  • “Nivolumab”, 115 entries
  • “nivolumab”, 18 entries
  • “ONO-4538”, 13 entries
  • “BMS-936558 (MDX-1106)”, 5 entries
  • “Nivolumab + Relatlimab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.